tiprankstipranks
Trending News
More News >

Femasys Gains European Approval for FemBloc System

Story Highlights
  • Femasys received European CE mark approval for FemBloc, a non-surgical birth control.
  • FemBloc’s approval allows marketing in Europe, enhancing Femasys’ industry position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Femasys Gains European Approval for FemBloc System

Don’t Miss TipRanks’ Half-Year Sale

Femasys ( (FEMY) ) just unveiled an announcement.

On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.

The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Spark’s Take on FEMY Stock

According to Spark, TipRanks’ AI Analyst, FEMY is a Underperform.

Femasys is under significant financial pressure with persistent losses, negative cash flows, and a challenging operating environment. The possibility of Nasdaq delisting adds to the risks, despite efforts to strengthen leadership and pursue growth. Technical indicators and valuation metrics reflect current weaknesses and potential for improvement if strategic changes succeed.

To see Spark’s full report on FEMY stock, click here.

More about Femasys

Femasys Inc. is a leading biomedical innovator focused on addressing critical unmet needs in women’s health. The company offers a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, including FemaSeed for infertility treatment and FemVue for fallopian tube assessment. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its innovations in the U.S. and key international markets.

Average Trading Volume: 290,135

Technical Sentiment Signal: Sell

Current Market Cap: $26.27M

Learn more about FEMY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1